Erschienen in:
01.07.2005 | Adis Drug Profile
Clofarabine
A Viewpoint by Peter G. Steinherz
verfasst von:
Peter G. Steinherz
Erschienen in:
Pediatric Drugs
|
Ausgabe 4/2005
Einloggen, um Zugang zu erhalten
Excerpt
Chemotherapy directed at-risk groups can eliminate the disease in about 80% of children with acute lymphoblastic leukemia (ALL). The long-term event-free survival of those with acute myelogenous leukemia (AML) is only 40–50%. These advances were achieved over many years, in a step-wise manner, in multiple, sequential, randomized clinical trials. These trials compared the best available therapy with one or more new regimens that included either additional active drugs, new combinations of the drugs already used, novel intensification phases, or modified sanctuary-directed therapies. …